相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis A Randomized, Placebo-Controlled Trial
Judith Bellmann-Strobl et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome
Rafael de la Torre et al.
CLINICAL NUTRITION (2020)
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Jeremy Chataway et al.
LANCET NEUROLOGY (2020)
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial
Johannes Levin et al.
LANCET NEUROLOGY (2019)
Maternal High Fat Diet-Induced Obesity Modifies Histone Binding and Expression of Oxtr in Offspring Hippocampus in a Sex-Specific Manner
Kelly A. Glendining et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
Daniel Ontaneda et al.
LANCET (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements
Wolfgang Dekant et al.
TOXICOLOGY LETTERS (2017)
Therapeutic effects of EGCG: a patent review
Leewanshi Chakrawarti et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial
Rafael de la Torre et al.
LANCET NEUROLOGY (2016)
Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial
Anja Maehler et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2015)
Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies
Jesus Lovera et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
On the origin of EDSS
John F. Kurtzke
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
The activity of catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo
Mario Lorenz et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
Jeremy Chataway et al.
LANCET (2014)
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?
Anja Mähler et al.
EPMA Journal (2013)
Epigallocatechin-3-Gallate Ameliorates Experimental Autoimmune Encephalomyelitis by Altering Balance among CD4+ T-Cell Subsets
Junpeng Wang et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2012)
Where to go next with neuroprotection in multiple sclerosis?
Franz Fazekas
LANCET NEUROLOGY (2010)
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
Raju Kapoor et al.
LANCET NEUROLOGY (2010)
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
D. R. Altmann et al.
NEUROLOGY (2009)
Sample size recalculation in internal pilot study designs: A review
Tim Friede et al.
BIOMETRICAL JOURNAL (2006)
User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability
Paul A. Yushkevich et al.
NEUROIMAGE (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers
U Ullmann et al.
INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH (2004)
Longitudinal brain volume measurement in multiple sclerosis - Rate of brain atrophy is independent of the disease subtype
NF Kalkers et al.
ARCHIVES OF NEUROLOGY (2002)
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis
SM Smith et al.
NEUROIMAGE (2002)
分享论文
